PT-141 — compounding legality overview

Bremelanotide / approved product nuance

Common names: Bremelanotide, Vyleesi

PeptSense tracks PT-141 across federal 503A Bulks List chain steps, PCAC advisory context, and state board positions. Status is never inferred from forums or marketing sites — only published citations with effective dates.

Federal 503A snapshot (illustrative)

Latest published federal event for 503A compounding pharmacies. Sign in for your licensed states and facility type.

Summary

Honest curation baseline (2026-08-01): Bremelanotide has an approved product (Vyleesi). Compounding posture needs substance-specific citation — under_review. Not a legal determination.

Citation

FDA compounding hub

Effective

Aug. 1, 2026

Not a legal determination. Replace placeholder citations during curation.

Run a full lookup

Get federal + state lanes, chain steps, printable answer cards, and compliance documents for the states you license in.